{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:19:49Z","timestamp":1794961189804,"version":"4.9.1"},"reference-count":45,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2025,3,24]]},"DOI":"10.1080\/1750743x.2025.2491295","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:40:43Z","timestamp":1745581243000},"page":"309-316","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3347-9751","authenticated-orcid":false,"given":"Alexandria","family":"Matic","sequence":"first","affiliation":[{"name":"University Health Network, University of Toronto","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-4883","authenticated-orcid":false,"given":"Vera","family":"Bril","sequence":"additional","affiliation":[{"name":"University Health Network, University of Toronto","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0110-z"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00776"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01726-y"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07577-7"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.933296"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2016.1214823"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.03.005"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00140-6"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2082946"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1505464"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2296126"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01933-1"},{"key":"e_1_3_4_21_1","unstructured":"UCB announces U.S. FDA approval of RYSTIGGO[\u00ae] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis [Internet]. 2023 [cited 2024 Sep 7]. Available from: https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-US-FDA-approval-of-RYSTIGGOR-rozanolixizumab-noli-for-the-treatment-of-adults-with-generalized-myasthenia-gravis"},{"key":"e_1_3_4_22_1","unstructured":"FDA CDER. Highlights of prescribing information. Rystiggo FDA; 2023 [cited 2023 Sep 6]."},{"key":"e_1_3_4_23_1","first-page":"853","article-title":"Efficacy and safety of Rozanolixizumab in moderate to severe generalized myasthenia gravis a phase 2 randomized control trial class of evidence criteria for rating therapeutic and diagnostic studies NPub.Org\/coe","volume":"96","author":"Bril V","year":"2021","unstructured":"Bril V, Benatar M, Andersen H, et al. Efficacy and safety of Rozanolixizumab in moderate to severe generalized myasthenia gravis a phase 2 randomized control trial class of evidence criteria for rating therapeutic and diagnostic studies NPub.Org\/coe. Investigators Neurol. 2021;96:853\u2013865.","journal-title":"Investigators Neurol"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205615"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241273036"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205057"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.122016"},{"key":"e_1_3_4_29_1","unstructured":"A study of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis (roMyG) [Internet]. [cited 2024 Sep 14]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06149559"},{"key":"e_1_3_4_30_1","unstructured":"A phase 3 open-label crossover study to evaluate self-administration of rozanolixizumab by study participants with generalized myasthenia gravis (gMG) [Internet]. [cited 2024 Sep 14]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05681715?a=24"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/22143602241308181"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01090-3"},{"key":"e_1_3_4_33_1","unstructured":"FDA Approves New treatment for myasthenia gravis [Internet]. 2021 Dec 17 [cited 2024 Sep 15]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-myasthenia-gravis"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.33590\/emjneurol\/BTET5689"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000903324.87754.45"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12247-x"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1479685"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03014-5"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-333112"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002003"},{"key":"e_1_3_4_41_1","unstructured":"A randomized double-blind placebo-controlled multicenter phase 3 pivotal study with an open-label extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with 1171 myelin Oligodendrocyte Glycoprotein (MOG) antibody-associated dis ease (MOG-AD). [Internet]. 2023 [cited 2024 Sep 15]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05063162"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000903336.22071.b3"},{"key":"e_1_3_4_43_1","unstructured":"UCB announces rozanolixizumab BLA for the treatment of general ized myasthenia gravis filed with U.S. FDA and designated for priority review. 2023 Jan 6. https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/ucb-announces-rozanolixizumab-bla-for-the-treatment-of-generalized-myasthenia-gravis-filed-with-us-fda-and-designated-for-priority-review"},{"key":"e_1_3_4_44_1","unstructured":"UCB announces approval of RYSTIGGO[\u00ae] (rozanolixizumab) and generalized\u00ae] (zilucoplan) for the treatm [Internet]. 2023 [cited 2024 Sep 16]. Available from: https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-approval-of-RYSTIGGOR-rozanolixizumab-and-ZILBRYSQR-zilucoplan-for-the-treatment-of-adult-patients-with-generalized-myasthenia-gravis-in-Japan"},{"key":"e_1_3_4_45_1","unstructured":"UCB announces European Commission approval of RYSTIGGO[\u00ae]\u25bc (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe [Internet]. [cited 2024 Sep 14]. https:\/\/www.ucb.com\/newsroom\/pressreleases\/article\/ucb-announces-europeancommission-approval-of-rystiggorv-rozanolixizumabfor-the-treatment-of-adults-with-generalizedmyasthenia-gravis-in-europe"},{"key":"e_1_3_4_46_1","unstructured":"Rozanolixizumab approved to treat adult patients with the autoimmune disease generalised myasthenia gravis [Internet]. 2024 [cited 2024 Sep 16]. Available from: https:\/\/www.gov.uk\/government\/news\/rozanolixizumab-approved-to-treat-adult-patients-with-the-autoimmune-disease-generalised-myasthenia-gravis"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.1531"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1750743X.2025.2491295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:57:05Z","timestamp":1747645025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1750743X.2025.2491295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,24]]}},"alternative-id":["10.1080\/1750743X.2025.2491295"],"URL":"https:\/\/doi.org\/10.1080\/1750743x.2025.2491295","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}